المؤلفون: Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson

المصدر: BMC Health Services Research, Vol 24, Iss 1, Pp 1-8 (2024)

مصطلحات موضوعية: Metastatic renal cell carcinoma, VEGFR tyrosine kinase inhibitor (TKI), Adverse event, Claims analysis, Third-line treatment, Cost of care, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1472-6963

URL الوصول: https://doaj.org/article/8ef7bbd24a304d5b9b93e0aceb84d027